Klebsiella Pneumoniae Infection Drug Market Report

Europe Klebsiella Pneumoniae Infection Drug Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jan 24, 2020
  • PAGES：215
  • REPORT CODE：GMM447490
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Klebsiella Pneumoniae Infection Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.4% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Klebsiella Pneumoniae Infection Drug Market Segmentations:

    By Player:

    • Phico Therapeutics Ltd

    • Nosopharm SAS

    • Tetraphase Pharmaceuticals Inc

    • Kyorin Pharmaceutical Co Ltd

    • ImmunoClin Corp

    • Debiopharm International SA

    • Acies Bio doo

    • F. Hoffmann-La Roche Ltd

    • Pfizer Inc

    • F Hoffmann-La Roche Ltd

    • Syntiron LLC

    • Evaxion Biotech ApS

    • Appili Therapeutics

    • Peptilogics Inc

    • Shionogi & Co Ltd

    • Innovation Pharmaceuticals Inc

    • Melinta Therapeutics Inc

    • Sarepta Therapeutics Inc

    By Type:

    • ATI-1503

    • CA-824

    • CC-1807

    • Cefiderocol

    • Debio-1454

    • EBX-004

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Klebsiella Pneumoniae Infection Drug Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of ATI-1503 from 2014 to 2026

    • 1.3.2 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of CA-824 from 2014 to 2026

    • 1.3.3 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of CC-1807 from 2014 to 2026

    • 1.3.4 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Cefiderocol from 2014 to 2026

    • 1.3.5 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Debio-1454 from 2014 to 2026

    • 1.3.6 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of EBX-004 from 2014 to 2026

    • 1.3.7 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Clinic from 2014 to 2026

    • 1.4.3 Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Klebsiella Pneumoniae Infection Drug Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Klebsiella Pneumoniae Infection Drug by Major Types

      • 3.4.1 Market Size and Growth Rate of ATI-1503

      • 3.4.2 Market Size and Growth Rate of CA-824

      • 3.4.3 Market Size and Growth Rate of CC-1807

      • 3.4.4 Market Size and Growth Rate of Cefiderocol

      • 3.4.5 Market Size and Growth Rate of Debio-1454

      • 3.4.6 Market Size and Growth Rate of EBX-004

      • 3.4.7 Market Size and Growth Rate of Others

    4 Segmentation of Klebsiella Pneumoniae Infection Drug Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Klebsiella Pneumoniae Infection Drug by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Klebsiella Pneumoniae Infection Drug for Hospital

      • 4.4.2 Market Size and Growth Rate of Klebsiella Pneumoniae Infection Drug for Clinic

      • 4.4.3 Market Size and Growth Rate of Klebsiella Pneumoniae Infection Drug for Others

    5 Market Analysis by Major Regions

    • 5.1 Europe Klebsiella Pneumoniae Infection Drug Production Analysis by Top Regions

    • 5.2 Europe Klebsiella Pneumoniae Infection Drug Consumption Analysis by Top Regions

    • 5.3 Europe Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.3 France Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    6 Product Circulation of Klebsiella Pneumoniae Infection Drug Market among Top Countries

    • 6.1 Top 5 Export Countries in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 7.1 Germany Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 7.2 Germany Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    8. UK Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 8.1 UK Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 8.2 UK Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    9. France Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 9.1 France Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 9.2 France Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    10. Italy Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 10.1 Italy Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 10.2 Italy Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    11. Spain Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 11.1 Spain Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 11.2 Spain Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    12. Poland Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 12.1 Poland Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 12.2 Poland Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    13. Russia Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 13.1 Russia Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 13.2 Russia Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    14. Switzerland Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 14.1 Switzerland Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 14.2 Switzerland Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    15. Turkey Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 15.1 Turkey Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 15.2 Turkey Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Top Countries

      • 16.3.1 Denmark Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 16.3.2 Finland Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 16.3.3 Norway Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 16.3.4 Sweden Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 16.3.6 Iceland Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Top Countries

      • 17.3.1 Belgium Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 17.3.2 Netherlands Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 17.3.3 Luxembourg Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Landscape Analysis by Top Countries

      • 18.3.1 Estonia Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 18.3.2 Latvia Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

      • 18.3.3 Lithuania Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Phico Therapeutics Ltd

      • 19.1.1 Phico Therapeutics Ltd Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Nosopharm SAS

      • 19.2.1 Nosopharm SAS Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Tetraphase Pharmaceuticals Inc

      • 19.3.1 Tetraphase Pharmaceuticals Inc Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Kyorin Pharmaceutical Co Ltd

      • 19.4.1 Kyorin Pharmaceutical Co Ltd Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 ImmunoClin Corp

      • 19.5.1 ImmunoClin Corp Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Debiopharm International SA

      • 19.6.1 Debiopharm International SA Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Acies Bio doo

      • 19.7.1 Acies Bio doo Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 F. Hoffmann-La Roche Ltd

      • 19.8.1 F. Hoffmann-La Roche Ltd Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Pfizer Inc

      • 19.9.1 Pfizer Inc Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 F Hoffmann-La Roche Ltd

      • 19.10.1 F Hoffmann-La Roche Ltd Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Syntiron LLC

      • 19.11.1 Syntiron LLC Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Evaxion Biotech ApS

      • 19.12.1 Evaxion Biotech ApS Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Appili Therapeutics

      • 19.13.1 Appili Therapeutics Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Peptilogics Inc

      • 19.14.1 Peptilogics Inc Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Shionogi & Co Ltd

      • 19.15.1 Shionogi & Co Ltd Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Innovation Pharmaceuticals Inc

      • 19.16.1 Innovation Pharmaceuticals Inc Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Melinta Therapeutics Inc

      • 19.17.1 Melinta Therapeutics Inc Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Sarepta Therapeutics Inc

      • 19.18.1 Sarepta Therapeutics Inc Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    The List of Tables and Figures (Totals 113 Figures and 155 Tables)

    • Figure Product Picture

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of ATI-1503 from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of CA-824 from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of CC-1807 from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Cefiderocol from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Debio-1454 from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of EBX-004 from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Clinic from 2014 to 2026

    • Figure Europe Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure UK Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure France Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Klebsiella Pneumoniae Infection Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Klebsiella Pneumoniae Infection Drug Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Klebsiella Pneumoniae Infection Drug

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Klebsiella Pneumoniae Infection Drug by Different Types from 2014 to 2026

    • Table Consumption Share of Klebsiella Pneumoniae Infection Drug by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of ATI-1503

    • Figure Market Size and Growth Rate of CA-824

    • Figure Market Size and Growth Rate of CC-1807

    • Figure Market Size and Growth Rate of Cefiderocol

    • Figure Market Size and Growth Rate of Debio-1454

    • Figure Market Size and Growth Rate of EBX-004

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Klebsiella Pneumoniae Infection Drug by Different End-Users from 2014 to 2026

    • Table Consumption Share of Klebsiella Pneumoniae Infection Drug by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Clinic

    • Figure Market Size and Growth Rate of Others

    • Table Europe Klebsiella Pneumoniae Infection Drug Production by Major Regions

    • Table Europe Klebsiella Pneumoniae Infection Drug Production Share by Major Regions

    • Figure Europe Klebsiella Pneumoniae Infection Drug Production Share by Major Countries and Regions in 2014

    • Table Europe Klebsiella Pneumoniae Infection Drug Consumption by Major Regions

    • Table Europe Klebsiella Pneumoniae Infection Drug Consumption Share by Major Regions

    • Table Germany Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table UK Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table France Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Italy Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Spain Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Poland Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Russia Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Switzerland Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Turkey Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Klebsiella Pneumoniae Infection Drug Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Germany Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Germany Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Germany Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table UK Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table UK Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table UK Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table UK Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table France Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table France Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table France Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table France Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Italy Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Italy Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Italy Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Italy Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Spain Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Spain Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Spain Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Spain Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Poland Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Poland Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Poland Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Poland Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Russia Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Russia Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Russia Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Russia Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Switzerland Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Switzerland Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Switzerland Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Turkey Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Turkey Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Turkey Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Klebsiella Pneumoniae Infection Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Klebsiella Pneumoniae Infection Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Klebsiella Pneumoniae Infection Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Klebsiella Pneumoniae Infection Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Phico Therapeutics Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Phico Therapeutics Ltd

    • Figure Sales and Growth Rate Analysis of Phico Therapeutics Ltd

    • Figure Revenue and Market Share Analysis of Phico Therapeutics Ltd

    • Table Product and Service Introduction of Phico Therapeutics Ltd

    • Table Company Profile and Development Status of Nosopharm SAS

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nosopharm SAS

    • Figure Sales and Growth Rate Analysis of Nosopharm SAS

    • Figure Revenue and Market Share Analysis of Nosopharm SAS

    • Table Product and Service Introduction of Nosopharm SAS

    • Table Company Profile and Development Status of Tetraphase Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Tetraphase Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Tetraphase Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Tetraphase Pharmaceuticals Inc

    • Table Product and Service Introduction of Tetraphase Pharmaceuticals Inc

    • Table Company Profile and Development Status of Kyorin Pharmaceutical Co Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kyorin Pharmaceutical Co Ltd

    • Figure Sales and Growth Rate Analysis of Kyorin Pharmaceutical Co Ltd

    • Figure Revenue and Market Share Analysis of Kyorin Pharmaceutical Co Ltd

    • Table Product and Service Introduction of Kyorin Pharmaceutical Co Ltd

    • Table Company Profile and Development Status of ImmunoClin Corp

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ImmunoClin Corp

    • Figure Sales and Growth Rate Analysis of ImmunoClin Corp

    • Figure Revenue and Market Share Analysis of ImmunoClin Corp

    • Table Product and Service Introduction of ImmunoClin Corp

    • Table Company Profile and Development Status of Debiopharm International SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Debiopharm International SA

    • Figure Sales and Growth Rate Analysis of Debiopharm International SA

    • Figure Revenue and Market Share Analysis of Debiopharm International SA

    • Table Product and Service Introduction of Debiopharm International SA

    • Table Company Profile and Development Status of Acies Bio doo

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Acies Bio doo

    • Figure Sales and Growth Rate Analysis of Acies Bio doo

    • Figure Revenue and Market Share Analysis of Acies Bio doo

    • Table Product and Service Introduction of Acies Bio doo

    • Table Company Profile and Development Status of F. Hoffmann-La Roche Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of F. Hoffmann-La Roche Ltd

    • Figure Sales and Growth Rate Analysis of F. Hoffmann-La Roche Ltd

    • Figure Revenue and Market Share Analysis of F. Hoffmann-La Roche Ltd

    • Table Product and Service Introduction of F. Hoffmann-La Roche Ltd

    • Table Company Profile and Development Status of Pfizer Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer Inc

    • Figure Sales and Growth Rate Analysis of Pfizer Inc

    • Figure Revenue and Market Share Analysis of Pfizer Inc

    • Table Product and Service Introduction of Pfizer Inc

    • Table Company Profile and Development Status of F Hoffmann-La Roche Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffmann-La Roche Ltd

    • Figure Sales and Growth Rate Analysis of F Hoffmann-La Roche Ltd

    • Figure Revenue and Market Share Analysis of F Hoffmann-La Roche Ltd

    • Table Product and Service Introduction of F Hoffmann-La Roche Ltd

    • Table Company Profile and Development Status of Syntiron LLC

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Syntiron LLC

    • Figure Sales and Growth Rate Analysis of Syntiron LLC

    • Figure Revenue and Market Share Analysis of Syntiron LLC

    • Table Product and Service Introduction of Syntiron LLC

    • Table Company Profile and Development Status of Evaxion Biotech ApS

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Evaxion Biotech ApS

    • Figure Sales and Growth Rate Analysis of Evaxion Biotech ApS

    • Figure Revenue and Market Share Analysis of Evaxion Biotech ApS

    • Table Product and Service Introduction of Evaxion Biotech ApS

    • Table Company Profile and Development Status of Appili Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Appili Therapeutics

    • Figure Sales and Growth Rate Analysis of Appili Therapeutics

    • Figure Revenue and Market Share Analysis of Appili Therapeutics

    • Table Product and Service Introduction of Appili Therapeutics

    • Table Company Profile and Development Status of Peptilogics Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Peptilogics Inc

    • Figure Sales and Growth Rate Analysis of Peptilogics Inc

    • Figure Revenue and Market Share Analysis of Peptilogics Inc

    • Table Product and Service Introduction of Peptilogics Inc

    • Table Company Profile and Development Status of Shionogi & Co Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shionogi & Co Ltd

    • Figure Sales and Growth Rate Analysis of Shionogi & Co Ltd

    • Figure Revenue and Market Share Analysis of Shionogi & Co Ltd

    • Table Product and Service Introduction of Shionogi & Co Ltd

    • Table Company Profile and Development Status of Innovation Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Innovation Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Innovation Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Innovation Pharmaceuticals Inc

    • Table Product and Service Introduction of Innovation Pharmaceuticals Inc

    • Table Company Profile and Development Status of Melinta Therapeutics Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Melinta Therapeutics Inc

    • Figure Sales and Growth Rate Analysis of Melinta Therapeutics Inc

    • Figure Revenue and Market Share Analysis of Melinta Therapeutics Inc

    • Table Product and Service Introduction of Melinta Therapeutics Inc

    • Table Company Profile and Development Status of Sarepta Therapeutics Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sarepta Therapeutics Inc

    • Figure Sales and Growth Rate Analysis of Sarepta Therapeutics Inc

    • Figure Revenue and Market Share Analysis of Sarepta Therapeutics Inc

    • Table Product and Service Introduction of Sarepta Therapeutics Inc

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US